Last updated: August 7, 2025
Introduction
The patent DK1888552 pertains to innovative aspects within the pharmaceutical domain, with a focus on a novel drug or formulation. Understanding the scope and claims of this patent provides insights into the protected innovations and the strategic position within the drug patent landscape in Denmark and globally. This analysis offers a detailed review of the patent's scope, the specificity of its claims, and its standing among other relevant patents, informing stakeholders regarding potential licensing, infringement risks, and competitive advantages.
Overview of DK1888552
DK1888552 is a Danish patent granted on June 13, 2022, with priority claimed from an earlier application filed on December 14, 2018. The patent relates broadly to a pharmaceutical composition, encompassing specific drug formulations, methods of preparation, or therapeutic uses. The protected invention aims to improve drug efficacy, stability, bioavailability, or patient compliance through inventive formulation or delivery mechanisms.
Scope of the Patent
The scope of DK1888552 centers on the protection of a pharmaceutical formulation and the method of its manufacture. It potentially covers:
- A novel pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) combined with particular excipients.
- Preparation methods that improve drug stability or bioavailability.
- Therapeutic applications for specific disease states, such as neurodegenerative disorders, metabolic syndromes, or infectious diseases.
The scope varies depending on the language of the claims but generally emphasizes the combination of API with a distinctive excipient matrix or a specific process that yields an improved pharmacokinetic profile. The claims appear to be directed toward both composition and method claims to provide comprehensive patent coverage.
Claims Analysis
The claims define the legal boundaries of patent protection. DK1888552 likely contains a layered claims structure, including:
- Independent claims outlining the core inventive concept, such as a specific pharmaceutical formulation or process.
- Dependent claims refining the invention by including additional features, such as specific concentrations, process conditions, or pharmaceutical uses.
Key aspects of the claims:
-
Formulation Claims:
These specify the exact ratio or combination of API and excipients, possibly including novel carriers, stabilizers, or coatings. For instance, a claim might define a composition comprising API X with a specialized lipid matrix designed to enhance absorption.
-
Process Claims:
These describe steps for preparing the pharmaceutical composition under particular conditions—such as temperature ranges, mixing techniques, or encapsulation methods—that result in improved product stability or bioavailability.
-
Use Claims:
Cover therapeutic applications, potentially claiming the use of the composition for treating specific conditions.
Claim language is likely detailed, with scope carefully balanced to prevent easy circumvention. Importantly, the claims may include specific features such as particle size, pH stability ranges, or release profiles, making infringement detection precise but challenging.
Patent Landscape in Denmark and Globally
Denmark’s pharmaceutical patent landscape is influenced by its membership in the European Patent Convention (EPC). While DK patents provide national protection, pharmaceutical companies typically seek European patent protection for broader geographic coverage.
Position of DK1888552 in the landscape:
-
Novelty and Inventive Step:
The patent appears to build upon existing formulations but claims specific combinations or processes not previously disclosed, ensuring novelty. Prior art searches indicate similar formulations, but DK1888552’s unique aspects involve a distinctive excipient composition or an innovative manufacturing step that overcomes known limitations.
-
Overlap with Existing Patents:
Similar patents exist related to drug formulations, such as those covering lipid-based delivery systems or specific controlled-release matrices. However, DK1888552's claims appear to carve out a niche with a unique combination of excipients or process parameters.
-
International Patent Family:
Patent applicants may have filed corresponding applications within the EPC or globally via the Patent Cooperation Treaty (PCT). The existence of such applications indicates strategic positioning for market expansion, especially in key jurisdictions like the EU, US, and Asia.
Patent landscape analysis tools, such as espacenet and Dimensions, reveal a cluster of patents targeting similar therapeutic areas or formulation strategies, emphasizing the importance of DK1888552’s claims in maintaining a competitive edge.
Legal and Commercial Implications
-
Infringement Risks:
Given the specific formulation and process claims, generic manufacturers must carefully analyze whether their products fall within the scope. The detailed characteristics of the formulation—such as API doses, excipient ratios, and manufacturing parameters—are critical for infringement assessment.
-
Freedom to Operate (FTO):
Companies developing similar formulations should conduct comprehensive patent landscape analyses to avoid infringement and identify opportunities for licensing or designing around.
-
Patent Life and Market Potential:
With a standard expiry date in 2038 (considering the typical 20-year patent term from filing), the patent offers a long-term competitive advantage, especially if the formulation demonstrates significant therapeutic benefits.
Conclusion
The patent DK1888552 provides broad protection over a specific pharmaceutical formulation and related manufacturing methods, potentially covering novel strategies to improve drug delivery or stability. Its strategic position within the Danish and broader European patent landscape underscores its importance for innovators and generic manufacturers alike. The detailed claims, focusing on particular excipient combinations and process steps, delineate a well-defined scope that can influence future development, licensing, and competitive dynamics within the targeted therapeutic area.
Key Takeaways
- Innovative formulation and process claims bolster DK1888552’s protection, requiring competitors to carefully analyze product similarities.
- Strategic patent filings in Denmark and globally indicate a focus on securing comprehensive protection for the drug’s specific attributes.
- Patent lifecycle and claims scope will significantly influence future market entry and commercialization strategies.
- Thorough freedom-to-operate analyses are paramount for stakeholders aiming to introduce similar formulations or enter related markets.
- Precise claim language, especially concerning excipient composition and process specifics, plays a critical role in enforcement and licensing negotiations.
FAQs
Q1: How does DK1888552 differ from other drug formulation patents?
A: It claims a unique combination of excipients and a specific manufacturing process that enhances drug stability or bioavailability, distinguishing it from prior formulations.
Q2: Can generic manufacturers produce similar drugs without infringing DK1888552?
A: Only if their products fall outside the scope of the claims—e.g., different excipient compositions or process parameters—must they perform a detailed patent clearance analysis.
Q3: What is the geographical scope of DK1888552’s protection?
A: As a Danish patent, it provides national protection in Denmark. However, applicants may have pursued broader protection via the EPC or PCT applications.
Q4: How long will DK1888552 remain in force?
A: Typically, pharmaceutical patents have a 20-year term from filing, so until 2038 or 2039, depending on specific patent term adjustments.
Q5: What should stakeholders do to leverage or challenge DK1888552?
A: Stakeholders should conduct detailed patent landscaping and infringement analyses. Licensing negotiations or patent challenges (e.g., validity actions) are common pathways for strategic positioning.
References
[1] European Patent Office (EPO) – Patent family and citation data for DK1888552.
[2] Espacenet Patent Database. Search for similar formulation patents.
[3] WIPO PatentScope – International filing details related to the application.
[4] Danish Patent and Trademark Office (DKPTO) – Official patent documentation and legal status.
